Should We "RESPECT EPA" More Now? EPA and DHA for Cardiovascular Risk Reduction.

Abstract

PURPOSE OF REVIEW

There has been much debate surrounding the use of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for cardiovascular (CV) risk reduction.

RECENT FINDINGS

Recent trials of epa and DHA have offered conflicting evidence. Some demonstrate reduction in CV risk using epa alone in select populations. Others have demonstrated no benefit, with potential for side effects, such as new- onset atrial fibrillation. Both epa and DHA have favorable impact on lipids and inflammation, suggesting some biological plausibility for CV risk reduction. However, clinical trials of these agents have produced mixed results. Based on available evidence, epa may work better for CV risk than DHA and epa combined. The benefit of epa seems to be dose dependent, though higher doses may have more side effects. Further research is needed to define the role of epa and DHA in the landscape of CV risk reduction.